Umbilical cord stem cells for slowing vision loss in retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether stem cells from donated umbilical cord tissue can slow down or stop vision loss in people with retinitis pigmentosa, a condition that causes progressive blindness. You would receive these cells as injections around your eye and will be closely monitored with several vision tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your vision must be at least 20/100 on a standard eye chart (better than severe vision loss).
- You must have a measurable response in your cone cells (the cells that help you see color and sharp detail) on an electroretinogram (ERG) test.
- Your overall visual field (peripheral vision) must be at least 10 degrees wide.
- You must be willing to receive injections around the eye (peribulbar injections) containing stem cells from donated umbilical cord tissue.
- You must be able to attend regular checkups and complete vision tests and questionnaires as scheduled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single injection of umbilical cord stem cells around the eye can safely help slow or improve vision loss from retinitis pigmentosa, a genetic eye disease. It also checks how long any benefits might last, using regular eye tests and a quality-of-life survey.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This study tests a new treatment that uses your own stem cells to create retinal cells, which are then placed in your eye. The goal is to see if this can help improve vision for people with advanced age-related macular degeneration.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.